Braveheart Bio starts Phase 3 oHCM trial, reports Q2 2026 results
The company began its LIONHEART-HCM Phase 3 study in obstructive hypertrophic cardiomyopathy and reported $122.8 million in cash as of June 30, 2026, rising to $527.3 million after its August IPO.
Braveheart Bio said it has moved BHB-1893 into a Phase 3 trial in obstructive hypertrophic cardiomyopathy (oHCM), following Phase 2 oHCM results announced in March 2026, with the new trial, called LIONHEART-HCM, designed to test BHB-1893 against metoprolol in symptomatic oHCM patients using a randomized, double-blind, active-comparator design across multiple regions and centers.1 CEO Travis Murdoch said sites are being activated and patients are screening for the study, with the company on track to dose its first patient this year.1 The company said it continues to expect an interim analysis from LIONHEART-HCM in the second half of 2027.1
On the non-obstructive HCM (nHCM) side, Braveheart Bio in May 2026 announced with Hengrui Pharmaceuticals Co., Ltd. results from a randomized, double-blind, placebo-controlled Phase 2 trial of HRS/BHB-1893 in nHCM, presented as a late-breaker at the 2026 Heart Failure Association of the European Society of Cardiology meeting.1 In that trial, BHB-1893-treated patients showed rapid, substantial, statistically significant reductions in cardiac biomarker secondary endpoints that reversed during drug washout, along with higher functional status and exercise capacity versus baseline, and statistically significant, dose-dependent echo improvements in myocardial relaxation, hemodynamic benefit, and cardiac remodeling including diastolic function versus placebo.1 The company added that no intervention-cohort patients required drug interruption for LVEF reductions.1 Braveheart Bio said it now has an active U.S. IND and expects to start the global Phase 3 NOBLEHEART-HCM trial in nHCM in the first half of 2027.1
On financing, the company reported cash and cash equivalents of $122.8 million as of June 30, 2026, compared with $89.2 million at year-end 2025.1 Following its August 2026 IPO, which generated aggregate net proceeds of approximately $404.5 million,1 cash on an as-adjusted basis would have been approximately $527.3 million.1 Braveheart Bio said this funding is expected to support projected operating expenses and capital expenditures into 2029.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.